Join Growin Stock Community!

Alzamend neuro, inc.ALZN.US Overview

US StockHealthcare
(No presentation for ALZN)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ALZN AI Insights

ALZN Overall Performance

ALZN AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ALZN Recent Performance

-3.25%

Alzamend neuro, inc.

0.05%

Avg of Sector

-0.31%

S&P500

ALZN PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ALZN Key Information

ALZN Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ALZN Profile

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and AL002 that completed preclinical stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

Price of ALZN

ALZN FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ALZN Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.87
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.72
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.87
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
-
PB Ratio
1.72
Price-to-FCF
-
Gross Margin
-%
Net Margin
-%
Revenue Growth (YoY)
-%
Profit Growth (YoY)
-%
3-Year Revenue Growth
-%
3-Year Profit Growth
-%

  • When is ALZN's latest earnings report released?

    The most recent financial report for Alzamend neuro, inc. (ALZN) covers the period of 2026Q2 and was published on 2025/10/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ALZN's short-term business performance and financial health. For the latest updates on ALZN's earnings releases, visit this page regularly.

  • How much cash does ALZN have?

    At the end of the period, Alzamend neuro, inc. (ALZN) held Total Cash and Cash Equivalents of 4.45M, accounting for 0.87 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is ALZN's EPS continuing to grow?

    According to the past four quarterly reports, Alzamend neuro, inc. (ALZN)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.3. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ALZN?

    Alzamend neuro, inc. (ALZN)'s Free Cash Flow (FCF) for the period is -1.17M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 65.55% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.